Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma

Matthew M K Chan*, Richard F. Kefford, Matteo Carlino, Arthur Clements, Nicholas Manolios

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

87 Citations (Scopus)

Abstract

We report the acute onset of polyarticular inflammatory arthritis in 2 patients receiving the immune check-point inhibitor, pembrolizumab (MK-3475), anti-PD1 drug for metastatic melanoma after 14 and 11 months therapy, respectively. The first patient had severe tenosynovitis, synovitis, bone marrow edema, and myositis, whereas the second patient had predominantly synovitis and tenosynovitis. Good symptomatic control was obtained with bisphosphonates and salazopyrin, avoiding the use of T-cell immunosuppressants. These cases raise important questions on whether anti-PD1 therapy allows preexisting autoimmune T-cell clones to escape tolerance by suppressing regulatory T cells or whether they allow autoimmunity to develop de novo. These conditions heighten our awareness of complications associated with the clinical use of these agents, and provide a prototypical model for future research into the understanding of autoimmunity.

Original languageEnglish
Pages (from-to)37-39
Number of pages3
JournalJournal of Immunotherapy
Volume38
Issue number1
DOIs
Publication statusPublished - 14 Jan 2015
Externally publishedYes

Keywords

  • Anti-PD1 antibody
  • Arthritis
  • Immunotherapy
  • Melanoma
  • PD1

Fingerprint Dive into the research topics of 'Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma'. Together they form a unique fingerprint.

Cite this